Description
Factor VIII:C Polyclonal Antibody – HRP Conjugated
Affinity’s Factor VIII:C Polyclonal Antibody – HRP Conjugated is the base level of our horseradish peroxidase conjugated Factor VIII:C antibodies. The purity of IgG is typically 90% and is provided in a solution of HEPES buffered saline containing 50% glycerol (v/v). The titre is essentially the same as the starting antiserum and each vial typically contains the amount of IgG recovered from one milliliter of antiserum however this IgG has been conjugated with Horseradish Peroxidase as an enzyme reporter. This Factor VIII:C Polyclonal Antibody – HRP Conjugated is generally intended for use as labeled primary antibodies in applications such as immunoassay and immunoblotting.
Product Code: SAF8C-HRP
Retail Product Size: 0.2mg vial
Host Animal: Sheep Anti-Human Factor VIII:C Polyclonal Antibody – HRP Conjugated
Species Cross Reactivity: View Chart
Product Datasheet: Factor VIII F8 Polyclonal Antibody - hrp conjugated anti-human sheep IgG
Description of Factor VIII
Factor VIII (formerly referred to as antihemophilic globulin and Factor VIII:C) is a large glycoprotein (320 kDa) that circulates in plasma at approximately 200 ng/ml. Synthesized in the liver, the majority of Factor VIII is cleaved during expression, resulting in a heterogeneous mixture of partially cleaved forms of FVIII ranging in size from 200-280 kDa. The FVIII is stabilized by association with von Willebrand Factor to form a FVIII-vWF complex required for the normal survival of FVIII in vivo (t1/2 of 8-12 hours).
F.VIII is a pro-cofactor that is activated through limited proteolysis by thrombin. In this process F.VIIIa dissociates from vWF to combine with activated Factor IX, calcium and a phospholipid surface where it is an essential cofactor in the assembly of the Factor X activator complex. Once dissociated from vWF, FVIIIa is susceptible to inactivation by activated Protein C and by non-enzymatic decay.
Hemophilia A is a congenital bleeding disorder resulting from an X-chromosome-linked deficiency of FVIII. The severity of the deficiency generally correlates with the severity of the disease. Some Hemophiliacs (~10%) produce a FVIII protein that is partially or totally inactive. The production of neutralizing antibodies to FVIII also occurs in 5-20% of Hemophiliacs 1-3.
References and Review
- Lollar P, Fay PJ, Fass DN; Factor VIII and Factor VIIIa. Methods in Enzymology, 222, pg 122, 1993.
- Hoyer, LW, Wyshock EG, Colman RW, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 109-133, J.B. Lippincott Co., Philadelphia, 1994.
- Pittman DD, Kaufman RJ. Structure-Function Relationships of Factor VIII Elucidated through Recombinant DNA Technology. Thromb. Haemostasis. 61:161-165, 1989.
